Eris Lifesciences Ltd (ERIS) AI Stock Analysis

• Market Cap: ₹217.40B
• Dividend Yield: 0.45%
• Average Volume (3M): 2.07K
• Price to Earnings (P/E): 56.1
• Beta (1Y): 0.53
• Revenue Growth: 30.27%
• EPS Growth: 1.69%
• Country: IN
• Employees: 3,620
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 8.70
• Shares Outstanding: 136,213,550
• 10 Day Avg. Volume: 1,915
• 30 Day Avg. Volume: 2,071
• PEG Ratio: -5.23
• Price to Book (P/B): 6.64
• Price to Sales (P/S): 6.58
• P/FCF Ratio: 20.82
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 67 Neutral
• Price Target: ₹1,770.00 ▲(9.31% Upside)

Eris Lifesciences Ltd shows strong financial performance with robust revenue growth and healthy margins. However, technical indicators suggest potential bearish trends, and the stock appears overvalued based on its high P/E ratio. The low dividend yield further limits its attractiveness for income-focused investors.

Eris Lifesciences Ltd Business Overview & Revenue Model

Company Description

Eris Lifesciences Limited manufactures, markets, and distributes pharmaceutical products in India. It offers various branded formulations in various therapeutic areas, such as cardiovascular, anti–diabetes, anti-infective, antipyretics, vitamins/nutrients, gastroenterology, respiratory, gynecology, pediatrics, neurology, psychiatry, and pain/analgesics, as well as in-vitro fertilization, cosmetology, and dermatology. Eris Lifesciences Limited was incorporated in 2007 and is based in Ahmedabad, India.

How the Company Makes Money

Eris Lifesciences generates revenue primarily through the sales of its pharmaceutical products, particularly its branded generics. The company has a well-established distribution network that allows it to reach a broad customer base, including hospitals, pharmacies, and healthcare providers across India. Key revenue streams include prescription drugs for chronic diseases, which are often prescribed by healthcare professionals, and a range of over-the-counter medications. Additionally, ERIS may engage in partnerships with other pharmaceutical companies for co-marketing or distribution agreements, further enhancing its market reach and revenue potential. Factors contributing to its earnings include a strong focus on research and development to innovate new products, strategic marketing initiatives, and maintaining a robust supply chain to ensure product availability.

Eris Lifesciences Ltd Financial Statement Overview

Summary

Eris Lifesciences Ltd displays solid financial health with strong growth trajectories in revenue and cash flow. The company effectively manages its operational and financial resources, evidenced by robust margins and a solid equity base. While there are areas to monitor, such as cash balances and Free Cash Flow volatility, the overall outlook is positive.

Income Statement

Eris Lifesciences Ltd has shown impressive revenue growth over the years, with a significant jump from 2024 to 2025. The Gross Profit Margin remains strong, indicating efficient cost management. However, the Net Profit Margin has shown some fluctuations, indicating potential areas for improvement. The EBIT and EBITDA margins are robust, demonstrating solid operational efficiency.

Balance Sheet

The company maintains a healthy balance sheet with a solid equity base. The Debt-to-Equity Ratio is manageable, suggesting prudent financial leverage. The Return on Equity is strong, reflecting effective resource utilization. However, the decrease in cash and equivalents over the years may need monitoring.

Cash Flow

Eris Lifesciences Ltd has demonstrated strong growth in Operating Cash Flow, which supports its Net Income. The Free Cash Flow has seen significant improvement, indicating efficient capital expenditure management. However, the fluctuations in Free Cash Flow over the years highlight potential volatility in cash generation.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	29.37B	28.79B	19.91B	16.62B	13.26B	11.93B
Gross Profit	20.13B	21.49B	9.95B	13.09B	10.65B	9.51B
EBITDA	10.58B	10.17B	6.99B	5.48B	5.11B	4.39B
Net Income	3.87B	3.52B	3.92B	3.82B	4.06B	3.55B
Balance Sheet
Total Assets	0.00	70.33B	70.49B	36.67B	22.72B	18.35B
Cash, Cash Equivalents and Short-Term Investments	2.05B	2.28B	13.39B	892.43M	2.12B	1.31B
Total Debt	0.00	24.78B	27.81B	8.77B	844.07M	67.77M
Total Liabilities	-32.72B	37.61B	38.27B	14.47B	3.64B	2.58B
Stockholders Equity	32.72B	28.54B	25.86B	21.96B	19.08B	15.76B
Cash Flow
Free Cash Flow	0.00	9.10B	3.57B	-5.50B	2.57B	3.50B
Operating Cash Flow	0.00	10.65B	4.86B	2.92B	3.78B	3.75B
Investing Cash Flow	0.00	-799.70M	-18.55B	-9.82B	-3.20B	-3.23B
Financing Cash Flow	0.00	-8.81B	13.80B	6.88B	-446.99M	-823.95M

Eris Lifesciences Ltd Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1619.20
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ERIS, the sentiment is Positive. The current price of 1619.2 is above the 20-day moving average (MA) of 1602.06, below the 50-day MA of 1662.14, and above the 200-day MA of 1530.14, indicating a neutral trend. The MACD of -8.73 indicates Negative momentum. The RSI at 49.99 is Neutral, neither overbought nor oversold. The STOCH value of 78.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:ERIS.

Eris Lifesciences Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ERIS	―	₹217.40B	56.14	―	0.45%	30.27%	1.69%
GLAND	―	₹318.91B	41.40	―	0.94%	-2.34%	6.64%
GLAXO	―	₹465.11B	48.87	―	2.06%	6.65%	48.47%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GLENMARK	―	₹522.88B	69.69	―	0.13%	10.99%	―